Northstar All themes →
Home / Themes / Healthcare

Telemedicine

Digital Health & Med-TechHealthcare Updated 2026-08-11

Telehealth has matured from pandemic-era novelty into a scaled, commodity delivery channel — the investable question has shifted from adoption to unit economics, as the two largest listed pure-plays (Teladoc, Hims & Hers) both show growth decelerating sharply even as the broader market keeps compounding.

📈 What changed: Hims & Hers reported Q2 2026 revenue of $753.2M, up 38% YoY and above its own $680-700M guide, but posted a wider-than-expected $0.37/share GAAP loss on a ~12-point gross-margin c…

The Northstar view

Primary State
Scaled but Decelerating WatchCategory adoption is mature; unit growth has slowed sharply
Near-Term Value
Subscription & Health-Plan Revenue at Scale ActiveMulti-billion-dollar recurring revenue across the two largest names
Main Risk
GLP-1 Wedge Compression WatchBranded price cuts and FDA compounding rules squeeze the fastest-growing sub-segment; a fresh FTC/state privacy-and-billing suit against Hims & Hers adds acute legal risk
Conviction
Medium StableCategory is durable; individual-name growth trajectories are the open question
Next Trigger
Talkspace/UHS deal close and Q3 2026 earnings (dates TBD) 2026-Q3Hims & Hers beat on Q2 2026 revenue (+38% YoY, $753.2M) but missed on EPS/margin as GLP-1 and international mix compressed gross margin 12 points; next tests are the Talkspace/UHS close and Q3 earnings.

Six-indicator scorecard

IndicatorScoreReading
Maturity
higher is better · high confidence
73/100
Scaled and commodity for routine visits; GLP-1/weight-loss telehealth remains a fast-moving, regulator-sensitive sub-segment.
Evidence Strength
higher is better · high confidence
71/100
SEC filings and multiple independent market-research houses corroborate scale; growth-rate specifics vary by source.
Commercial Proximity
higher is better · high confidence
75/100
Large, real recurring revenue base, but growth has decelerated sharply from pandemic-era rates.
Capital & Policy Support
higher is better · high confidence
48/100
Reimbursement-flexibility extensions matter more than direct subsidy; deregulation is a tailwind, GLP-1 compounding rules are a headwind.
Crowding Risk
lower is better · high confidence
20/100
Positioning has de-rated sharply from pandemic-era highs; valuation is now closer to depressed than crowded for the two largest listed names.
Reflexivity Risk
lower is better · high confidence
64/100
Single events move these names sharply — GLP-1 regulatory news, earnings misses, and legal-risk headlines all drive outsized swings.

Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.

Related tickers

TDOCHIMSLFSTDOCSTALKGDRXAMWLLFMDTTALO.HE2413.T

See the full Telemedicine briefing

The public page is the summary (backed by 25 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.

Open in the appStart free →

The Northstar Signal — what moved across all 350+ themes and why, in your inbox. Free, no spam, one-click unsubscribe.

More in Healthcare

GLP-1 & the Metabolic Health RevolutionGLP-1 receptor agonists have become the fastest-adopted drug class in pharmaceutical hist…Longevity Biotech & the Biology of AgeingLongevity biotech is transitioning from high-concept science to early-stage clinical vali…Precision MedicineGenomic, molecular and AI-driven diagnostics are converging into a single treatment-selec…Diagnostic GenomicsLiquid biopsy and NGS-based screening are moving cancer detection upstream of diagnosis —…Gene EditingGene editing has crossed from proof-of-concept to a genuine, if still narrow, commercial…Cell TherapyCell therapy has moved past proof-of-concept into a genuine multi-billion-dollar commerci…mRNA TherapeuticsThe mRNA platform that COVID built is now being redirected at oncology and rare disease,…AI Drug DiscoveryAI drug discovery has attracted more capital in 2026 than any biotech subsector since imm…